Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme

Chris J Tyrrell, Heather Payne, William A See, David G McLeod, Manfred P Wirth, Peter Iversen, Jon Armstrong, Clive Morris, Casodex Early Prostate Cancer Trialists' Group

    61 Citationer (Scopus)

    Abstract

    The ongoing Early Prostate Cancer (EPC) programme is assessing bicalutamide ('Casodex') 150 mg, either alone or as adjuvant to treatment of curative intent, in patients with localised or locally advanced prostate cancer (n=8113). This paper presents an exploratory analysis of the subgroup of the EPC programme who received radiotherapy with curative intent (n=1370) in order to determine the efficacy (in terms of progression-free survival [PFS]) and tolerability of bicalutamide 150 mg in this setting.
    OriginalsprogEngelsk
    TidsskriftRadiotherapy & Oncology
    Vol/bind76
    Udgave nummer1
    Sider (fra-til)4-10
    Antal sider7
    ISSN0167-8140
    StatusUdgivet - 1 jul. 2005

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme'. Sammen danner de et unikt fingeraftryk.

    Citationsformater